Oncology

Latest News

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds

January 4th 2020

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds

Testicular cancer is the most common cancer to be diagnosed in men as younger men—those younger than age 40—and it can be particularly aggressive. Advances in therapy have improved survival rates, but if young men have chemotherapy after surgery, they may live with side effects for decades.

What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer

January 2nd 2020

What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer

Five issues in healthcare were spotlighted as key developments to watch; FDA to ban all e-cig vape flavors except for menthol and tobacco; Google AI system shown to improve detection of breast cancer through mammograms.

An Immune-Suppressing Target for Glioblastoma?

December 27th 2019

An Immune-Suppressing Target for Glioblastoma?

A team at The University of Texas MD Anderson Cancer Center in Houston led by original pioneers in immuno-oncology have published a paper in Nature Medicine that discusses an immune-suppressing enzyme that was strongly present in glioblastoma but not in 5 other tumor types the team studied.

December 19th 2019

Improving Survival in Lung Cancer: Commitment of The Lung Ambition Alliance

Giorgio Scagliotti, MD, PhD

For more than 45 years, the International Association for the Study of Lung Cancer has been working tirelessly toward a world without lung and other thoracic cancers. To add strength to our efforts we recently joined with other leading organizations in the lung cancer space to create a powerful force for change: The Lung Ambition Alliance

Future of BCC and CSCC Therapy

December 19th 2019

Future of BCC and CSCC Therapy

Second-Line Systemic Treatment of BCC

December 19th 2019

Second-Line Systemic Treatment of BCC

Systemic Therapy in BCC

December 19th 2019

Systemic Therapy in BCC

Electing for Surgery in the Management of BCC

December 19th 2019

Electing for Surgery in the Management of BCC

Overview of Basal Cell Carcinoma

December 19th 2019

Overview of Basal Cell Carcinoma

December 19th 2019

Toxicity Profile and Pseudoprogression

PD-1 and Other Systemic Treatment Options for CSCC

December 19th 2019

PD-1 and Other Systemic Treatment Options for CSCC

Using Immunotherapy in CSCC

December 19th 2019

Using Immunotherapy in CSCC

Systemic Treatment of CSCC

December 19th 2019

Systemic Treatment of CSCC

Standard of Care for CSCC

December 19th 2019

Standard of Care for CSCC

Overview of Cutaneous Squamous Cell Carcinoma

December 19th 2019

Overview of Cutaneous Squamous Cell Carcinoma

December 18th 2019

Radiation Oncologist Discusses Concerns With Incoming CMS Payment Model

Allison Inserro

As CMS prepares to move forward with new models of value-based cancer care, a radiation oncologist, speaking at the Institute for Value-Based Medicine®, discussed her findings regarding whether accountable care models had an effect on cancer care spending.

December 18th 2019

Hope and Some Skepticism Whether Oncology Payment Models Will Work

Allison Inserro

Coverage from the Institute for Value-Based Medicine® session held in Nashville, Tennessee.

Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines

December 18th 2019

Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines

In cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), there is a greater risk of symptomatic heart failure in the first year following initiation of anthracycline treatment.

Government-Insured Patients With Breast Cancer Face a Higher Risk of Death

December 17th 2019

Government-Insured Patients With Breast Cancer Face a Higher Risk of Death

Patients with breast cancer who have government insurance face a higher risk of death, according to a retrospective study presented at the 2019 San Antonio Breast Cancer Symposium on December 13.

December 17th 2019

From the Editor-in-Chief: Lead, Follow, or Get Out of the Way

Joseph Alvarnas, MD

Dr Alvarnas is editor-in-chief of Evidence-Based Oncology.™ He is vice president of Government Affairs, senior medical director for Employer Strategy, and associate clinical professor, Hematology & Hematologic Cell Transplantation, City of Hope, Duarte, Califonia.

December 16th 2019

Provider Perspective: Stephen M. Schleicher, MD, MBA, Addresses Accountability Versus Control in Oncology Care First

An article Schleicher co-wrote in JAMA Oncology, which appeared the day before the announcement of Oncology Care First, offered insights into the need for changes to the original OCM.

December 16th 2019

Provider Perspective: Kashyap Patel, MD, Sees Collaboration Going Into Oncology Care First

Kashyap Patel, MD, the chief executive officer of Carolina Blood and Cancer Care Associates—a leading OCM practice—and associate editor of Evidence-Based Oncology™ (EBO), said he’s optimistic about Oncology Care First.

December 16th 2019

Can Cancer Care Lead the Way Toward a Value-Based Future?

Keely Macmillan, MPH

A senior vice president of Archway Health discusses challenges and opportunities of the proposed Oncology Care First model.

Anthracycline, Radiation Treatment for Childhood Cancer Shown to Increase Risk of Adult Breast Cancer

December 12th 2019

Anthracycline, Radiation Treatment for Childhood Cancer Shown to Increase Risk of Adult Breast Cancer

There was a 37% increase in childhood cancer survival between 1975 and 2010. With more children receiving chemotherapy and radiation to treat their diseases, leading to more survivors, awareness has grown of the belated effects of those treatments once patients reach adulthood.

December 11th 2019

Outcome Measures for Oncology Alternative Payment Models: Practical Considerations and Recommendations

Jakub P. Hlávka, PhD Pei-Jung Lin, PhD Peter J. Neumann, ScD

This review presents a set of evidence-based outcome measures for oncology alternative payment models, drawing on evidence from existing and proposed quality measures.

Supplemental MRI of Very Dense Breast Tissue Finds Early Cancers, at Higher Risk of False Positives

December 11th 2019

Supplemental MRI of Very Dense Breast Tissue Finds Early Cancers, at Higher Risk of False Positives

A recent study published in The New England Journal of Medicine says that women with dense breast tissue who undergo supplemental magnetic resonance imaging (MRI) tests have lower rates of interval cancers than those who receive only mammography tests, although they also had higher rates of false positive tests.

Jennifer Atkins Describes Blue Cross Blue Shield's Commitment to Innovations in Oncology

December 8th 2019

Jennifer Atkins Describes Blue Cross Blue Shield's Commitment to Innovations in Oncology

Blue Cross Blue Shield is dedicated to maintaining local relationships to ensure they can provide the best care continuum to patients, said Jennifer Atkins, MBA, vice president of Network Solutions at Blue Cross Blue Shield.

NHS Staffing Shortages Behind Delays in Cancer Diagnoses for Patients in UK

December 7th 2019

NHS Staffing Shortages Behind Delays in Cancer Diagnoses for Patients in UK

Patients waited about 2 months longer than necessary for a cancer diagnosis in the United Kingdom, according to a study published this week.

Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy

December 4th 2019

Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy

Heart issues in patients with cancer and survivors can present themselves months or years after treatment.

This Week in Managed Care: November 29, 2019

November 29th 2019

This Week in Managed Care: November 29, 2019

This week, the top managed care news included research that may hold the key to slowing progression of multiple sclerosis; Humana says it is saving billions of dollars through value-based care; the challenges of rural healthcare delivery.

...

19 20 21 22 23 24 25 26 27

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions